Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP-2101 + incomplete freund's adjuvant
- Development stage
- Unknown
- Lead developer
- OSE Immunotherapeutics
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
EP-2101 + incomplete freund's adjuvant is a combination of a neo-epitope-based cancer vaccine (EP-2101, also known as OSE-2101 or Tedopi) and incomplete Freund’s adjuvant. EP-2101 consists of 10 optimized neo-epitopes derived from five tumor-associated antigens, designed to stimulate a specific cytotoxic T-cell response against various cancer cell types. Incomplete Freund’s adjuvant (IFA) is a water-in-oil emulsion of paraffin oil and mannide monooleate, serving as an immunologic adjuvant to prolong antigen exposure and enhance the immune response, particularly a Th2-biased antibody response. This combination aims to improve anti-tumor immunity by enhancing T-cell and antibody-mediated responses. EP-2101 is being developed primarily for non-small cell lung cancer, pancreatic ductal adenocarcinoma, and ovarian cancer, and is administered subcutaneously with IFA as the adjuvant[1][5][9][4].
- Brand names
- Tedopi
- Other names
- OSE 2101OSE2101OSE-2101EP-2101EP2101EP 2101TexopiMulti-neo-epitope vaccine OSE-2101
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ERBB2 (Erb-b2 receptor tyrosine kinase 2)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)MAGEA2 (Melanoma-associated antigen 2)MAGEA3 (Melanoma-associated antigen 3)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on EP-2101 + incomplete freund's adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP-2101 + incomplete freund's adjuvant.